1632484-77-5
Chemical Structure
Ceritinib-d7
Synonym(s): LDK378 d7
- CAS. Nr.: 1632484-77-5
- Formula:C28H29D7ClN5O3S
- Molecular Weight:565.18
IUPAC Name: 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(5-methyl-4-(piperidin-4-yl)-2-((propan-2-yl-d7)oxy)phenyl)pyrimidine-2,4-diamine
InChIKey: VERWOWGGCGHDQE-WFBMWZOZSA-N
SMILES: CC1=C(C2CCNCC2)C=C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3)=C1
Biological Activity: Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1]. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ceritinib-d7 | 98.00% | Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ceritinib (Standard) | 99.72% | Ceritinib (Standard) is the analytical standard of Ceritinib (HY-15656). This product is intended for research and analytical applications. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ceritinib | 99.95% | Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. [Content Brief]
